Kuramitsu Kaori, Fukumoto Takumi, Kinoshita Hisoka, Kido Masahiro, Takebe Atsushi, Tanaka Motofumi, Iwasaki Takeshi, Tominaga Masahiro, Ku Yonson
Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe City, Hyogo, Japan.
Department of Surgery, National Hospital Organization Kobe Medical Center, Nishi-Ochiai, Suma-ku, Kobe City, Hyogo, Japan.
Ann Transplant. 2016 Jun 21;21:380-5. doi: 10.12659/aot.897958.
BACKGROUND Portal vein thrombus (PVT) has been an absolute contraindication for liver transplantation because of technical difficulties and inadequate vessel graft supply. With recent surgical innovations many difficulties have been overcome and PVT is no longer a contraindication to liver transplantation. MATERIAL AND METHODS From June 2000 to December 2014, 72 patients underwent living donor liver transplantation at Kobe University Hospital, with a focus on the high-grade PVT cases and analysis of modified PV reconstruction technique and clinical course. RESULTS Four recipients (5.6%) developed Yerdel classification grade III PVT and 2 recipients (2.8%) developed grade IV PVT. There were no statistically significant differences between the severity of PVT grades by sex (p=0.77), recipient age (p=0.49), model for end-stage liver disease (MELD) score (p=0.68), graft-recipient weight ratio (GWRW) (p=0.15), graft type of right or left lobe (p=0.55), original liver disease (p=0.09), or intra-operative bleeding (p=0.21). Four grade III recipients were anastomosed with SMV, and 2 grade IV recipients were anastomosed with coronary vein, both of which were interpositioned with vein grafts. Only 1 recipient had died of hepatocellular carcinoma recurrence by 1.5 years after liver transplantation, and all 5 remaining severe PVT recipients survived. Overall 1- and 5-year survival rates for grade 0, I, and II recipients were 78.8% and 62.4%, respectively; 75.0% and 75.0%, respectively, for grade III recipients; and 100% and 100%, respectively, for grade IV recipients (p=0.54). CONCLUSIONS High-grade PVT had comparable survival without the recurrence of PVT after living donor liver transplantation.
背景 由于技术困难和血管移植物供应不足,门静脉血栓形成(PVT)一直是肝移植的绝对禁忌证。随着近期手术创新,许多困难已被克服,PVT不再是肝移植的禁忌证。材料与方法 2000年6月至2014年12月,72例患者在神户大学医院接受活体肝移植,重点关注高级别PVT病例以及改良门静脉重建技术和临床过程分析。结果 4例受者(5.6%)发生耶德尔分类III级PVT,2例受者(2.8%)发生IV级PVT。PVT分级严重程度在性别(p=0.77)、受者年龄(p=0.49)、终末期肝病模型(MELD)评分(p=0.68)、移植物与受者体重比(GWRW)(p=0.15)、右叶或左叶移植物类型(p=0.55)、原发病(p=0.09)或术中出血(p=0.21)方面无统计学显著差异。4例III级受者与肠系膜上静脉(SMV)吻合,2例IV级受者与冠状静脉吻合,两者均插入静脉移植物。肝移植后仅1例受者在1.5年时死于肝细胞癌复发,其余5例严重PVT受者均存活。0、I和II级受者的总体1年和5年生存率分别为78.8%和62.4%;III级受者分别为75.0%和75.0%;IV级受者分别为100%和100%(p=0.54)。结论 高级别PVT在活体肝移植后有相当的生存率且无PVT复发。